Latest post

Arshad Khanani: “Initial data of phase 1 trial of THR-687 point to clinical efficacy”

Arshad Khanani, M.D., M.A. about the clinical phase 1 data of THR-687.

back of the eye diseases, science community,

Positive phase 1 data indicate THR-687 could be an effective therapy for patients with DME

Oxurion kick-started 2020 with positive topline data from phase 1 clinical trial evaluating THR-687 for treatment of DME.